{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:12:57Z","timestamp":1782303177395,"version":"3.54.5"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>This study aimed to assess the diagnostic efficacy of the PRIMARY score, based on the <jats:sup>18<\/jats:sup>F-labeled prostate-specific membrane antigen (PSMA-1007) positron emission tomography (PET)\/computed tomography (CT) with multiparametric magnetic resonance imaging (mpMRI) PI-RADS, in detecting clinically significant prostate cancer (csPCa).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>In this retrospective cohort study, 137 patients with suspected prostate cancer (PCa) underwent [<jats:sup>18<\/jats:sup>F]PSMA-1007 PET\/CT and mpMRI before transrectal ultrasound (TRUS)-guided needle biopsy was performed. Patients were categorized into csPCa and non-csPCa groups based on histopathological findings. The diagnostic performance of total prostate-specific antigen (TPSA), maximum standardized uptake value (SUVmax), the standardized Prostate Imaging Reporting and Data System (PI-RADS v2. 1) of mpMRI, and the PRIMARY score was evaluated using receiver operating characteristic (ROC) curves. The area under the curve (AUC), sensitivity, and specificity were calculated. Factors with a P-value &amp;lt;0.05 from the univariate analysis were included in a binary logistic regression model to develop a predictive model. Differences in the AUCs for TPSA, SUVmax, PI-RADS v2.1, the PRIMARY score, and the combined model were compared using MedCalc software. Statistical significance was set at P&amp;lt;0.05.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 137 patients evaluated, 67.2% (92) were in csPCa and 32.8% (45) in the non-csPCa group (15 with low-grade PCa [GS 3\u00a0+\u00a03] and 30 with benign prostatic hyperplasia or acute or chronic prostatitis). TPSA, SUVmax, PI-RADSv2.1, and the PRIMARY score significantly differed between the two groups (P&amp;lt;0.013). The AUCs for TPSA, SUVmax, PI-RADSv2.1, and PRIMARY score were 0.699, 0.898, 0.878, and 0.910, respectively, with corresponding diagnostic sensitivities of 53.3%, 87.0%, 90.2%, and 83.7%, and specificities of23.0%, 65. 1%, 42.6%, and 58.5%, respectively. The predictive ROC curve analysis of the model revealed an AUC of 0.968, with 91.3% sensitivity, and 84.6% specificity. MedCalc analysis showed that the AUC of the model was superior compared with that of SUVmax, PI-RADS v2.1 Score, and the PRIMARY score. The difference was statistically significant (Z= 2.273, 3.485, 2.761; P=0.023, 0.000, 0.005).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The 5-grade PRIMARY score, derived from [<jats:sup>18<\/jats:sup>F]PSMA-1007 PET\/CT in conjunction with the PI-RADSv2.1 score, offers enhanced discrimination of csPCa.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1589212","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:15:57Z","timestamp":1750220157000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Diagnostic value of [18F]PSMA-1007 PET\/CT based on PRIMARY score combined with mpMRI in clinically significant prostate cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Zhilong","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HaiTong","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YanMei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000541152","article-title":"Prediction of clinically significant prostate cancer using multiparametric mri, biparametric mri, and clinical parameters","volume":"109","author":"Oberneder","year":"2025","journal-title":"Urol Int"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-021-00949-7","article-title":"Clinically significant prostate cancer (Cspca) detection with various prostate sampling schemes based on different cspca definitions","volume":"21","author":"Fei","year":"2021","journal-title":"BMC Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24475","article-title":"The use of 68 ga-psma pet\/ct to stratify patients with pi-rads 3 lesions according to clinically significant prostate cancer risk","volume":"83","author":"Jinhui","year":"2022","journal-title":"Prostate"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000001617","article-title":"The utility of 68ga-psma pet\/ct in poorly differentiated metastatic prostate cancer","volume":"42","author":"Demirkol","year":"2017","journal-title":"Clin Nucl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 international society of urological pathology (Isup) consensus conference on gleason grading of prostatic carcinoma : definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and overtreatment of prostate cancer","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-6051.24.06118-4","article-title":"Prostate cancer diagnostic pathway in men with lower urinary tract symptoms or performing opportunistic screening: the italian society of urology (Siu) position paper","volume":"76","author":"Ficarra","year":"2024","journal-title":"Minerva Urol Nephrol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric mri and trus biopsy in prostate cancer (Promis): A paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"Eau-eanm-estro-esur-isup-siog guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13162697","article-title":"Prostate mri and psma-pet in the primary diagnosis of prostate cancer","volume":"13","author":"Cereser","year":"2023","journal-title":"Diagnostics"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04863-2","article-title":"68ga-psma pet\/ct targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: A prospective randomized single-centre study","volume":"48","author":"Le-Le","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.21037\/tau-22-832","article-title":"Prediction of clinically significant prostate cancer using a novel (68)Ga-psma pet-ct and multiparametric mri-based model","volume":"12","author":"Cheng","year":"2023","journal-title":"Transl Androl Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-018-0048-7","article-title":"68ga-psma pet\/ct vs. Mpmri for locoregional prostate cancer staging: correlation with final histopathology","volume":"21","author":"Berger","year":"2018","journal-title":"Prostate Cancer prostatic Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12880-025-01557-9","article-title":"Which psma pet\/ct interpretation criteria most effectively diagnose prostate cancer? A retrospective cohort study","volume":"25","author":"Ma","year":"2025","journal-title":"BMC Med Imaging"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-023-04002-z","article-title":"Psma pet imaging in the diagnosis and management of prostate cancer","volume":"48","author":"Houshmand","year":"2023","journal-title":"Abdom Radiol (NY)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263448","article-title":"The primary score: using intraprostatic (68)Ga-psma pet\/ct patterns to optimize prostate cancer diagnosis","volume":"63","author":"Emmett","year":"2022","journal-title":"J Nucl Med"},{"key":"B18","article-title":"Small extracellular vesicle-associated mir-6068 promotes aggressive phenotypes of prostate cancer through mir-6068\/hic2\/sirt1 axis","volume":"12","author":"Shahenda","year":"2022","journal-title":"Am J Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.958065","article-title":"Fully automated detection and localization of clinically significant prostate cancer on mr images using a cascaded convolutional neural network&13","volume":"12","author":"Lina","year":"2022","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/RLU.0000000000004951","article-title":"The primary score: diagnostic performance and added value compared with mri in detecting clinically significant prostate cancer","volume":"49","author":"Shikuan","year":"2024","journal-title":"Clin Nucl Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/ph15091109","article-title":"A high-affinity (64)Cu-labeled ligand for pet imaging of hepsin: design, synthesis, and characterization","volume":"15","author":"Park","year":"2022","journal-title":"Pharm (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00259-021-05189-3","article-title":"Performance of [ 68 ga]Ga-psma-11 pet\/ct in patients with recurrent prostate cancer after prostatectomy\u2014a multi-centre evaluation of 2533 patients","volume":"48","author":"Afshar-Oromieh","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B23","doi-asserted-by":"publisher","first-page":"k3519","DOI":"10.1136\/bmj.k3519","article-title":"Prostate cancer screening with prostate-specific antigen (Psa) test: A systematic review and meta-analysis","volume":"362","author":"Dragan","year":"2018","journal-title":"BMJ (Clinical Res ed)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/bco2.62","article-title":"The diagnostic accuracy of multiparametric mri for detection and localization of prostate cancer depends on the affected region","volume":"2","author":"Martina","year":"2020","journal-title":"BJUI Compass"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14111184","article-title":"Transition from transrectal to transperineal mri-fusion prostate biopsy does not comprise detection rates of clinically significant prostate cancer at a tertiary care center","volume":"14","author":"Hoeh","year":"2024","journal-title":"Diagnostics"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41416-024-02934-x","article-title":"The accuracy of fluorine 18-labelled prostate-specific membrane antigen pet\/ct and mri for diagnosis of prostate cancer in psa grey zone","volume":"132","author":"Luo","year":"2024","journal-title":"Br J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.11.003","article-title":"Early oncological outcomes in patients who underwent staging prostate-specific membrane antigen positron emission tomography\/computed tomography compared with conventional imaging before radical prostatectomy and extended pelvic lymph node dissection","volume":"8","author":"Ettema","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7150\/thno.58140","article-title":"Establishment and prospective validation of an suvmax cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by 68ga-psma pet\/ct: A real-world study","volume":"11","author":"Jianhua","year":"2021","journal-title":"Theranostics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"10963","DOI":"10.1038\/s41598-020-67385-9","article-title":"Comparison of 68ga-psma-617 pet\/ct with mpmri for the detection of pca in patients with a psa level of 4\u201320 ng\/ml before the initial biopsy","volume":"10","author":"Yu","year":"2020","journal-title":"Sci Rep"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1589212\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:15:57Z","timestamp":1750220157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1589212\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":29,"alternative-id":["10.3389\/fonc.2025.1589212"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1589212","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"article-number":"1589212"}}